Myriad Genetics (MYGN) Q2 2026 earnings — TrendMatrix coverage

Adjusted EPS

-$0.25

Estimate

-$0.06

Surprise

-332.7%

Score at report (before → after)

4.7 → 5.3/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

Myriad Genetics (MYGN) reported a wider loss than forecast — adjusted EPS of -$0.25 against the -$0.06 estimate (a 332.7% shortfall). TrendMatrix's engine moved from Sell (4.7/10) to Hold at 5.3/10 after the report — the engine's score rose despite the miss.

TrendMatrix currently rates MYGN Sell at 4.1/10.

1 of the last 4 quarters beat the estimate; this quarter's -332.7% surprise compares with a +20.2% four-quarter average. Next scheduled report: 2026-11-04.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$6.51

Stop

$6.06

Model outputs from TrendMatrix’s engine as of 2026-10-29 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Diagnostics & Research

Market cap

$634.2M

P/E (fwd)

-11.3

52-week range

$2.74–$8.38

Off 52-week high

22.3%

RSI (14)

80

Volume vs avg

0.07×

Score today

4.1/10